Ulla Olsson-Strömberg

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Lauseker, Michael; Sacha, Tomasz; Klamova, Hana; Yakoleva, Julia et al.

Part of Leukemia, p. 751-758, 2026

• DOI for Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
• Download full text (pdf) of Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Luukkainen, Katariina; Purhonen, Mikko; Tatun, Mikael; Hung, Kevin et al.

Part of HemaSphere, 2026

• DOI for Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
• Download full text (pdf) of Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Part of Leukemia, p. 2968-2977, 2025

• DOI for Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Download full text (pdf) of Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Part of Leukemia, p. 781-787, 2024

• DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso et al.

Part of Leukemia, p. 1722-1730, 2024

• DOI for Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Lauseker, Michael; Sacha, Tomasz; Klamova, Hana; Yakoleva, Julia et al.

Part of Leukemia, p. 751-758, 2026

• DOI for Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
• Download full text (pdf) of Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Luukkainen, Katariina; Purhonen, Mikko; Tatun, Mikael; Hung, Kevin et al.

Part of HemaSphere, 2026

• DOI for Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
• Download full text (pdf) of Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Purhonen, Mikko; Tatun, Mikael; Luukkainen, Katariina; Hung, Kevin et al.

Part of Leukemia, p. 2968-2977, 2025

• DOI for Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
• Download full text (pdf) of Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne et al.

Part of Leukemia, p. 781-787, 2024

• DOI for Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial
• Download full text (pdf) of Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib: interim results from the DAstop2 trial

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, Fabio; Mahon, Francois-Xavier; Richter, Johan; Piciocchi, Alfonso et al.

Part of Leukemia, p. 1722-1730, 2024

• DOI for Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

Brioli, Annamaria; Lomaia, Elza; Fabisch, Christian; Sacha, Tomasz et al.

Part of Leukemia, p. 1072-1080, 2024

• DOI for Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
• Download full text (pdf) of Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, Francois-Xavier; Pfirrmann, Markus; Dulucq, Stephanie; Hochhaus, Andreas et al.

Part of Journal of Clinical Oncology, 2024

• DOI for European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

Huuhtanen, Jani; Adnan-Awad, Shady; Theodoropoulos, Jason; Forsten, Sofia et al.

Part of Leukemia, p. 109-125, 2024

• DOI for Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
• Download full text (pdf) of Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study

Dahlen, Torsten; Flygt, Hjalmar; Lubking, Anna; Olsson-Strömberg, Ulla et al.

Part of Leukemia, p. 1156-1159, 2023

• DOI for The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
• Download full text (pdf) of The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska, Monika; Cai, Huan; Mansson, Alma; Shen, Jingyi et al.

Part of Blood, p. 73-89, 2023

• DOI for Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
• Download full text (pdf) of Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Geelen, Inge G. P.; Gullaksen, Stein-Erik; Ilander, Mette M.; Olsson-Strömberg, Ulla et al.

Part of Annals of Hematology, p. 1395-1408, 2023

• DOI for Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients

Vaivade, Aina; Wiberg, Anna; Khoonsari, Payam Emami; Carlsson, Henrik et al.

Part of Lipids in Health and Disease, 2023

• DOI for Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
• Download full text (pdf) of Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening

Schaal, Wesley; Ameur, Adam; Olsson-Strömberg, Ulla; Hermansson, Monica et al.

Part of Cancer Informatics, p. 1-8, 2022

• DOI for Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
• Download full text (pdf) of Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study

Dahlen, Torsten; Edgren, Gustaf; Ljungman, Per; Flygt, Hjalmar et al.

Part of American Journal of Hematology, p. 421-430, 2022

• DOI for Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
• Download full text (pdf) of Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study

IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M. J. et al.

Part of Journal of Clinical Investigation, 2022

• DOI for IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
• Download full text (pdf) of IFN-alfa with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Flygt, Hjalmar; Sandin, Fredrik; Dahlén, Torsten; Dremaine, Arta et al.

Part of British Journal of Haematology, p. 915-921, 2021

• DOI for Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
• Download full text (pdf) of Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan et al.

Part of European Journal of Haematology, p. 617-623, 2021

• DOI for Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study
• Download full text (pdf) of Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh et al.

Part of Leukemia, p. 2416-2418, 2021

• DOI for Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI
• Download full text (pdf) of Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR: final report from AFTER-SKI

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Söderlund, Stina; Persson, Inger; Ilanderd, Mette; Guilhot, Joelle et al.

Part of Leukemia Research, 2020

• DOI for Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Abboud, Camille; Gjertsen, Bjørn Tore et al.

Part of Leukemia, p. 2125-2137, 2020

• DOI for Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
• Download full text (pdf) of Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation

Wiberg, Anna; Strömberg, Ulla Ohlsson; Herman, Stephanie; Kultima, Kim et al.

Part of Biology of blood and marrow transplantation, p. 50-57, 2020

• DOI for Profound but Transient Changes in the Inflammatory Milieu of the Blood During Autologous Hematopoietic Stem Cell Transplantation

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Lubking, Anna; Dreimane, Arta; Sandin, Fredrik; Isaksson, Cecilia et al.

Part of Bone Marrow Transplantation, p. 1764-1774, 2019

• DOI for Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore et al.

Part of Oncoimmunology, 2019

• DOI for Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
• Download full text (pdf) of Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar et al.

Part of American Journal of Hematology, p. 1236-1243, 2019

• DOI for Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
• Download full text (pdf) of Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Saussele, Susanne; Richter, Johan; Guilhot, Joelle; Gruber, Franz X. et al.

Part of The Lancet Oncology, p. 747-757, 2018

• DOI for Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Löf, Liza; Arngården, Linda; Olsson-Strömberg, Ulla; Siart, Benjamin et al.

Part of Scientific Reports, p. 1-9, 2017

• DOI for Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
• Download full text (pdf) of Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

El Missiry, Mohamed; Hjorth-Hansen, Henrik; Richter, Johan; Olsson-Strömberg, Ulla et al.

Part of PLOS ONE, 2017

• DOI for Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
• Download full text (pdf) of Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Rajala, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu et al.

Part of Journal of Cancer Research and Clinical Oncology, p. 1543-1554, 2017

• DOI for Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

KIT signaling is dispensable for human mast cell progenitor development

Dahlin, Joakim S.; Ekoff, Maria; Grootens, Jennine; Löf, Liza et al.

Part of Blood, p. 1785-1794, 2017

• DOI for KIT signaling is dispensable for human mast cell progenitor development

CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON-A2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDDUTCHCML009)

Geelen, I.; Strömberg, Ulla Ohlsson; Mustjoki, S.; Richter, J. et al.

Part of Haematologica, p. 435-435, 2017

CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS

Pfirrmann, M.; Mahon, F-X; Guilhot, J.; Richter, J. et al.

Part of Haematologica, p. 153-153, 2017

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander, M; Olsson-Strömberg, Ulla; Schlums, H; Guilhot, J et al.

Part of Leukemia, p. 1108-1116, 2017

• DOI for Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
• Download full text (pdf) of Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

Söderlund, Stina; Dahlén, Torsten; Sandin, Fredrik; Olsson-Strömberg, Ulla et al.

Part of European Journal of Haematology, p. 57-66, 2017

• DOI for Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era: a report from the Swedish CML register

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Gunnarsson, N.; Höglund, Martin; Stenke, L.; Sandin, F. et al.

Part of Leukemia, p. 1825-1827, 2017

• DOI for No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia

Dolinska, Monika; Piccini, Alexandre; Wong, Wan Man; Gelali, Eleni et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 378-384, 2017

• DOI for Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia
• Download full text (pdf) of Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 (+)CD38(-) stem and progenitor cells in chronic myeloid leukemia

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Giustacchini, Alice; Thongjuea, Supat; Barkas, Nikolaos; Woll, Petter S. et al.

Part of Nature Medicine, p. 692-+, 2017

• DOI for Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Warfvinge, Rebecca; Geironson, Linda; Sommarin, Mikael N. E.; Lang, Stefan et al.

Part of Blood, p. 2384-2394, 2017

• DOI for Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik et al.

Part of Leukemia Research, p. 95-103, 2016

• DOI for Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Plasma Proteomics In Chronic Myeloid Leukemia Patients Before And After Initiation Of Tyrosine Kinase Inhibitor Therapy Reveals Induced Th1 Immunity And Loss Of Angiogenic Stimuli

Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, H. et al.

Part of Haematologica, p. 730-730, 2016

In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Skoglund, Karin; Richter, Johan; Olsson-Strömberg, Ulla; Bergquist, Jonas et al.

Part of Therapeutic Drug Monitoring, p. 230-238, 2016

• DOI for In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients

Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence

Gunnarsson, Niklas; Sandin, Fredrik; Höglund, Martin; Stenke, Leif et al.

Part of European Journal of Haematology, p. 387-392, 2016

• DOI for Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence

Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Hjorth-Hansen, H.; Stentoft, J.; Richter, J.; Koskenvesa, P. et al.

Part of Leukemia, p. 1853-1860, 2016

• DOI for Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Pla Flow; A Flow Cytometry-Based Assay For Detection Of Bcr-Abl Fusion Protein In Blood Cells From Cml Patients

Löf, Liza; Olsson-Strömberg, Ulla; Landegren, Ulf; Kamali-Moghaddam, Masood

Part of Haematologica, p. 457-458, 2016

Assessment Of Therapy Response In Chronic Myeloid Leukemia Via 1 Month Bcr-Abl1 Transcript Decline

El Missiry, M.; Hjorth-Hansen, H.; Richter, J.; Olsson-Strömberg, Ulla et al.

Part of Haematologica, p. 63-63, 2016

Stopping Tyrosine Kinase Inhibitors In A Very Large Cohort Of European Chronic Myeloid Leukemia Patients: Results Of The Euro-Ski Trial

Richter, J.; Mahon, F. X.; Guilhot, J.; Hjorth-Hansen, H. et al.

Part of Haematologica, p. 22-23, 2016

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

Gunnarsson, N.; Höglund, Martin; Stenke, L.; Wallberg-Jonsson, S. et al.

Part of Leukemia, p. 1562-1567, 2016

• DOI for Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

El Missiry, Mohamed; Awad, Shady Adnan; Rajala, Hanna L.; Al-Samadi, Ahmed et al.

Part of Journal of Cancer Research and Clinical Oncology, p. 1041-1050, 2016

• DOI for Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study

Dahlen, Torsten; Edgren, Gustaf; Lambe, Mats; Höglund, Martin et al.

Part of Annals of Internal Medicine, p. 161-166, 2016

• DOI for Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study

Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing

Cavelier, Lucia; Ameur, Adam; Häggqvist, Susana; Höijer, Ida et al.

Part of BMC Cancer, 2015

• DOI for Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
• Download full text (pdf) of Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

Karlsson, Hannah; Svensson, Emma; Gigg, Camilla; Jarvius, Malin et al.

Part of PLOS ONE, 2015

• DOI for Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
• Download full text (pdf) of Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015

• DOI for The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta et al.

Part of European Journal of Haematology, p. 243-250, 2015

• DOI for Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
• Download full text (pdf) of Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

Gunnarsson, Niklas; Stenke, Leif; Höglund, Martin; Sandin, Fredrik et al.

Part of British Journal of Haematology, p. 683-688, 2015

• DOI for Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

FLOW CYTOMETRY-BASED ASSAY FOR DETECTION OF BCR-ABL FUSION PROTEIN IN BLOOD CELLS FROM CML PATIENTS

Löf, Liza; Olsson-Strömberg, Ulla; Landegren, Ulf; Kamali-Moghaddam, Masood

Part of Haematologica, p. 694-695, 2015

PROGRESSION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO ADVANCED PHASE ON TKI THERAPY: A POPULATION BASED ANALYSIS FROM THE SWEDISH CML REGISTER

Söderlund, Stina; Dahlen, T.; Creignou, M.; Sandin, F. et al.

Part of Haematologica, p. 233-233, 2015

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

El Missiry, Mohamed; Adnan, Shady; Rajala, Hanna; Al-Samadi, Ahmed et al.

Part of Blood, 2015

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

El Missiry, Mohamed; Adnan, Shady; Rajala, Hanna; Al-Samadi, Ahmed et al.

Part of Blood, 2015

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Dolinska, Monika; Klang, Johannis; Xiao, Pingnan; Durgaryan, Andranik et al.

Part of Blood, 2015

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu et al.

Part of Blood, 2015

Mature, Adaptive-like CD56(DIM) NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Ilander, Mette; Schlums, Heinrich; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna et al.

Part of Blood, 2015

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Gunnarsson, Niklas; Höglund, Martin; Stenke, Leif; Jonsson, Solveig Wallberg et al.

Part of Blood, 2015

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Part of EuPA Open Proteomics, p. 37-47, 2014

• DOI for The use of multiplex platforms for absolute and relative protein quantification of clinical material

Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion

Karlsson, Hannah; Gigg, Camilla; Svensson, Emma; Larsson, Rolf et al.

Part of Molecular Therapy, 2014

CAR T Cells Express CD40L and Activates Human Dendritic Cells

Karlsson, Hannah; Gustafsson, Wictor; Olsson-Strömberg, Ulla; Savoldo, Barbara et al.

Part of Molecular Therapy, 2014

Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells

Ilander, Mette; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Kasanen, Tiina et al.

Part of Scandinavian Journal of Immunology, p. 467-468, 2014

Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Richter, Johan; Söderlund, Stina; Lübking, Anna; Dreimane, Arta et al.

Part of Journal of Clinical Oncology, p. 2821-2823, 2014

• DOI for Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study

Mahon, Francois-Xavier; Richter, Johan; Guilhot, Joelle; Muller, Martin C. et al.

Part of Blood, 2014

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Ilander, Mette Matilda; Olsson-Strömberg, Ulla; Lahteenmaki, Hanna; Tiina, Kasanen et al.

Part of Blood, 2014

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Gunnarsson, Niklas; Leif, Stenke; Höglund, Martin; Sandin, Fredrik et al.

Part of Blood, 2014

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Christiansson, Lisa; Söderlund, Stina; Svensson, Emma; Mustjoki, Satu et al.

Part of PLOS ONE, 2013

• DOI for Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
• Download full text (pdf) of Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Mustjoki, S.; Richter, J.; Barbany, G.; Ehrencrona, H. et al.

Part of Leukemia, p. 1520-1526, 2013

• DOI for Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Höglund, Martin; Sandin, Fredrik; Hellstrom, Karin; Bjoreman, Mats et al.

Part of Blood, p. 1284-1292, 2013

• DOI for Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells

Karlsson, H.; Svensson, E.; Lindqvist, C.; Hambardzumyan, K. et al.

Part of Human Gene Therapy, 2013

Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Simonsson, Bengt; Gedde-Dahl, Tobias; Markevarn, Berit; Remes, Kari et al.

Part of Blood, p. 3228-3235, 2011

• DOI for Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Lindqvist, Camilla A.; Christiansson, Lisa H.; Simonsson, Bengt; Enblad, Gunilla et al.

Part of Immunology, p. 371-376, 2010

• DOI for T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Olsson-Strömberg, Ulla; Hermansson, Monica; Lundan, Tuija; Ohm, Anne-Charlotte et al.

Part of European Journal of Haematology, p. 399-404, 2010

• DOI for Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib

Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival

Olsson-Strömberg, Ulla; Simonsson, Bengt; Ahlgren, Tomas; Björkholm, Magnus et al.

Part of The Hematology Journal, p. 462-466, 2004

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.